Company intelligence / Profile preview
Medikine, Inc.
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
Overview
Medikine’s lead candidate MDK‑703, an extended half-life IL‑7 mimetic Fc-fusion protein discovered using the PEPTIKINE™ platform, is in a Phase 1 trial in healthy volunteers. Preclinical data show activity on T cell memory populations and avoidance of neutralizing antibodies to native IL‑7. Additional programs are at preclinical or discontinued stages.
- Therapeutic areas
- OncologyImmunologyInfectious DiseasesHematology
- Modalities
- Synthetic peptides (PEPTIKINES™)Fc-fusion proteinsAntibody fusion proteins
- Industry
- Biotech
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Medikine, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Medikine, Inc..